nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Alive and Well: The Research Imperative
|
Dresser, Rebecca |
|
2012 |
40 |
4 |
p. 915-921 |
artikel |
2 |
An Empirical Examination of the Current State of Publically Available Nanotechnology Guidance Materials
|
Fleege, Laura |
|
2012 |
40 |
4 |
p. 751-762 |
artikel |
3 |
A Non-Paternalistic Model of Research Ethics and Oversight: Assessing the Benefits of Prospective Review
|
London, Alex John |
|
2012 |
40 |
4 |
p. 930-944 |
artikel |
4 |
A Portrait of Nanomedicine and its Bioethical Implications
|
Hall, Rebecca M. |
|
2012 |
40 |
4 |
p. 763-779 |
artikel |
5 |
Bad Blood Thirty Years Later: A Q&A with James H. Jones
|
Jones, James H. |
|
2012 |
40 |
4 |
p. 867-872 |
artikel |
6 |
Beyond Human Subjects: Risk, Ethics, and Clinical Development of Nanomedicines
|
Kimmelman, Jonathan |
|
2012 |
40 |
4 |
p. 841-847 |
artikel |
7 |
Building an Ethical Foundation for First-in-Human Nanotrials
|
Dresser, Rebecca |
|
2012 |
40 |
4 |
p. 802-808 |
artikel |
8 |
Concepts of Risk in Nanomedicine Research
|
Hogle, Linda F. |
|
2012 |
40 |
4 |
p. 809-822 |
artikel |
9 |
Currents in Contemporary Bioethics
|
McGuire, Amy L. |
|
2012 |
40 |
4 |
p. 1040-1046 |
artikel |
10 |
Ethical Dimensions of Disparities in Depression Research and Treatment in the Pharmacogenomic Era
|
Parker, Lisa S. |
|
2012 |
40 |
4 |
p. 886-903 |
artikel |
11 |
Handling Worker and Third-Party Exposures to Nanotherapeutics during Clinical Trials
|
Ramachandran, Gurumurthy |
|
2012 |
40 |
4 |
p. 856-864 |
artikel |
12 |
In Plain Sight: A Solution to a Fundamental Challenge in Human Research
|
Shepherd, Lois |
|
2012 |
40 |
4 |
p. 970-989 |
artikel |
13 |
IRB Decision-Making with Imperfect Knowledge: A Framework for Evidence-Based Research Ethics Review
|
Anderson, Emily E. |
|
2012 |
40 |
4 |
p. 951-969 |
artikel |
14 |
Medication Information for Patients with Limited English Proficiency: Lessons from the European Union
|
Regenstein, Marsha |
|
2012 |
40 |
4 |
p. 1025-1033 |
artikel |
15 |
More Than Cheating: Deception, IRB Shopping, and the Normative Legitimacy of IRBs
|
Spellecy, Ryan |
|
2012 |
40 |
4 |
p. 990-996 |
artikel |
16 |
Nanomedicine First-in-Human Research: Challenges for Informed Consent
|
King, Nancy M. P. |
|
2012 |
40 |
4 |
p. 823-830 |
artikel |
17 |
Practical Steps to Community Engaged Research: From Inputs to Outcomes
|
Isler, Malika Roman |
|
2012 |
40 |
4 |
p. 904-914 |
artikel |
18 |
Prudent Precaution in Clinical Trials of Nanomedicines
|
Marchant, Gary E. |
|
2012 |
40 |
4 |
p. 831-840 |
artikel |
19 |
Public Health and the Law
|
Hodge, James G. |
|
2012 |
40 |
4 |
p. 1034-1039 |
artikel |
20 |
Questions concerning the Clinical Translation of Cell-Based Interventions under an Innovation Pathway
|
Sugarman, Jeremy |
|
2012 |
40 |
4 |
p. 945-950 |
artikel |
21 |
Recommendations for Nanomedicine Human Subjects Research Oversight: An Evolutionary Approach for an Emerging Field
|
Fatehi, Leili |
|
2012 |
40 |
4 |
p. 716-750 |
artikel |
22 |
Research Ethics: Reexamining Key Concerns
|
King, Nancy M. P. |
|
2012 |
40 |
4 |
p. 865-866 |
artikel |
23 |
Responsible Conduct in Nanomedicine Research: Environmental Concerns beyond the Common Rule
|
Resnik, David B. |
|
2012 |
40 |
4 |
p. 848-855 |
artikel |
24 |
Rethinking Local Institutional Review Board (IRB) Review at State Health Departments: Implications for a Consolidated, Independent Public Health IRB
|
Perlman, David |
|
2012 |
40 |
4 |
p. 997-1007 |
artikel |
25 |
Revolution or Reform in Human Subjects Research Oversight
|
Joffe, Steven |
|
2012 |
40 |
4 |
p. 922-929 |
artikel |
26 |
The Challenge of Nanomedicine Human Subjects Research: Protecting Participants, Workers, Bystanders, and the Environment
|
Wolf, Susan M. |
|
2012 |
40 |
4 |
p. 712-715 |
artikel |
27 |
The Troubling Persistence of Race in Pharmacogenomics
|
Kahn, Jonathan |
|
2012 |
40 |
4 |
p. 873-885 |
artikel |
28 |
Toward Correlation in In Vivo and In Vitro Nanotoxicology Studies
|
Maurer-Jones, Melissa A. |
|
2012 |
40 |
4 |
p. 795-801 |
artikel |
29 |
What is Unique about Nanomedicine? The Significance of the Mesoscale
|
Khushf, George |
|
2012 |
40 |
4 |
p. 780-794 |
artikel |
30 |
What Research Ethics Should Learn from Genomics and Society Research: Lessons from the ELSI Congress of 2011
|
Henderson, Gail E. |
|
2012 |
40 |
4 |
p. 1008-1024 |
artikel |